Search
Mediwound Ltd
MDWDAdd to Watchlist
15.160USD
+0.340+2.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
194.84MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.29%
5 Days
+3.91%
1 Month
+10.17%
6 Months
-17.70%
Year to Date
-17.88%
1 Year
-20.71%
Key Figures
14.910Open
15.240High
52.68KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.41%Turnover Ratio
14.820Prev. Close
14.710Low
699.49KTurnover
LossP/E Static
3.90P/B
0.00%Div Yield TTM
-29.90%ROA
22.50552wk High
0.88Volume Ratio
-30.22MNet Profit
12.85MShares
-2.0990EPS TTM
0.18Beta
-52.35%ROE
14.14052wk Low
3.58%Amplitude
21.90%Gross Margin
194.84MMarket Cap
3.13Reward/Risk
2.54%Risk Rate
TradingKey Stock Score of Mediwound Ltd
Currency: USD Updated: 2026-07-02Key Insights
Mediwound Ltd's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 79 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.17.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mediwound Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Mediwound Ltd Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.96M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.96M.
Fairly Valued
The company’s latest PE is -7.22, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.42M shares, increasing 3.86% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 145.85K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
30.167
Target Price
+100.04%
Upside Space
Mediwound Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mediwound Ltd Info
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Ticker SymbolMDWD
CompanyMediwound Ltd
CEOGonen (Ofer)
Websitehttps://www.mediwound.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52823.700
-18.800 (-0.04%)
29649.700
+338.300 (+1.15%)
7502.900
+31.400 (+0.42%)
14953.000
+150.000 (+1.01%)
69626.000
+1478.000 (+2.17%)
6388.400
+35.600 (+0.56%)
68.573
+0.229 (+0.34%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4175.080
+53.170 (+1.29%)
FAQs
What is the current price of Mediwound Ltd (MDWD)?
The current price of Mediwound Ltd (MDWD) is 15.16.
What is the symbol of Mediwound Ltd?
The ticker symbol of Mediwound Ltd is MDWD.
What is the 52-week high of Mediwound Ltd?
The 52-week high of Mediwound Ltd is 22.50.
What is the 52-week low of Mediwound Ltd?
The 52-week low of Mediwound Ltd is 14.14.
What is the market capitalization of Mediwound Ltd?
The market capitalization of Mediwound Ltd is 194.84M.
Is Mediwound Ltd (MDWD) currently rated as Buy, Hold, or Sell?
According to analysts, Mediwound Ltd (MDWD) has an overall rating of Buy, with a price target of 30.17.
What is the Earnings Per Share (EPS TTM) of Mediwound Ltd (MDWD)?
The Earnings Per Share (EPS TTM) of Mediwound Ltd (MDWD) is -2.10.